CRDF: Cardiff Oncology Inc. Amount of Cash per Share

Corporate emblem and logo of Cardiff Oncology Inc. (CRDF)

Cardiff Oncology, Inc. (CRDF) drug development is protected by Western legal frameworks, which eliminates sanctions risks. On GURU.Markets, the cash position per share valuation demonstrates current liquidity, where the value of 0.42 reflects this status. The company's progress relies on AI protein modeling, while strategic alliances with clinics accelerate the creation of colon cancer therapies through onvasertib trials.

CRDF: cardiffoncology.com Cash per Share 07/04/2022 - 11/20/2026

Analytical breakdowns for Cardiff Oncology, Inc.

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:CRDF, Cardiff Oncology Inc.
Original product of Cardiff Oncology, Inc.

For Cardiff Oncology, Inc. (CRDF), which develops targeted inhibitors for cancer therapy, cash per share trends reflect the liquidity reserve necessary to complete clinical trials. This metric is calculated by dividing total cash by the number of shares outstanding, allowing investors to assess the asset's intrinsic value and its level of protection against market volatility during periods of zero revenue.